Sakar Healthcare soars after oncology unit receives EU GMP approval - Business Standard
| SAKAR Stock | 319.15 1.15 0.36% |
About 54% of Sakar Healthcare's investor base is interested to short. The analysis of overall sentiment of trading Sakar Healthcare Limited stock suggests that many investors are impartial at this time. Sakar Healthcare's investing sentiment overview a quick insight into current market opportunities from investing in Sakar Healthcare Limited. Many technical investors use Sakar Healthcare stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Sakar |
Sakar Healthcare soars after oncology unit receives EU GMP approval Business Standard
Read at news.google.com
 |
Sakar Healthcare Fundamental Analysis
We analyze Sakar Healthcare's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sakar Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sakar Healthcare based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Sakar Healthcare is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Sakar Healthcare Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sakar Healthcare stock to make a market-neutral strategy. Peer analysis of Sakar Healthcare could also be used in its relative valuation, which is a method of valuing Sakar Healthcare by comparing valuation metrics with similar companies.
Peers
Sakar Healthcare Related Equities
| COSMOFIRST | COSMO FIRST | 1.51 | ||||
| GATECHDVR | GACM Technologies | 1.04 | ||||
| PARAGMILK | Parag Milk | 0.09 | ||||
| HEUBACHIND | Heubach Colorants | 0.11 | ||||
| DELTAMAGNT | Delta Manufacturing | 0.21 | ||||
| RICOAUTO | Rico Auto | 0.38 | ||||
| CHEMCON | Chemcon Speciality | 0.64 | ||||
| KINGFA | Kingfa Science | 0.86 | ||||
| ARVIND | Arvind | 2.64 | ||||
| TBZ | Tribhovandas Bhimji | 2.67 |
Other Information on Investing in Sakar Stock
Sakar Healthcare financial ratios help investors to determine whether Sakar Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sakar with respect to the benefits of owning Sakar Healthcare security.